Loratidine buccal films for allergic rhinitis: development and evaluation

Abstract The objective of this study was to develop a novel patient compliant buccoadhesive film capable of providing a prolonged protection against allergic symptoms. Polymeric buccoadhesive films of loratidine were prepared using hydroxypropylmethyl cellulose (HPMC)-E5 and K100 blend and Eudragit®...

Full description

Saved in:
Bibliographic Details
Published in:Drug development and industrial pharmacy 2014-05, Vol.40 (5), p.625-631
Main Authors: Kumria, Rachna, Nair, Anroop B., Al-Dhubiab, Bandar E.
Format: Article
Language:English
Subjects:
Adhesiveness
Administration, Buccal
Allergic rhinitis
Animals
buccoadhesive
Chemistry, Pharmaceutical
Dosage Forms
Histamine H1 Antagonists, Non-Sedating - administration & dosage
Histamine H1 Antagonists, Non-Sedating - pharmacokinetics
Humans
Hypromellose Derivatives
in vitro
Loratadine - administration & dosage
Loratadine - pharmacokinetics
loratidine
Microscopy, Electron, Scanning
Oral Mucosal Absorption
polymer
Rhinitis, Allergic - drug therapy
Sus scrofa
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The objective of this study was to develop a novel patient compliant buccoadhesive film capable of providing a prolonged protection against allergic symptoms. Polymeric buccoadhesive films of loratidine were prepared using hydroxypropylmethyl cellulose (HPMC)-E5 and K100 blend and Eudragit® NE 30D as retardant. Films were prepared using solvent-casting method. The developed films were evaluated for physical properties, hydration, mucoadhesion time, drug release, etc. All the prepared films exhibited excellent mechanical strength and uniform drug content. Increase in drug content did not influence the physicomechanical properties of the film. The mucoadhesive strength of films was significantly enhanced with increase in HPMC content. Increase in Eudragit® NE 30 D content in the film decreases the hydration, erosion and drug release, but enhances the mucoadhesion time. Furthermore, the release of loratidine from the prepared films followed Hixson-Crowell kinetics. Studies in healthy human volunteers using placebo films indicate that the prepared films possess prolonged mucoadhesion in-vivo, and this could potentially lead to clinically relevant drug delivery system.
ISSN:0363-9045
1520-5762
DOI:10.3109/03639045.2014.884125